The drug prices review board was once a solution. It’s now a problem: Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada
Nigel Rawson and John Adams | Financial Post | 01 MAR 2023 Read article in
Opinions
CHP Opinions – Commentry from CHPI authors.
For drug access, Canadians with rare disorders are 40 years behind Americans
Nigel Rawson and John Adams | Financial Post | 24 JAN 2023
Suffer from a rare disorder in Canada? Good luck
Nigel Rawson and John Adams | Financial Post | 1 NOV 2022
Uncertainty about PMPRB price regulations will deter new drug launches in Canada
Nigel Rawson and Brett Skinner | Hill Times | 7 SEP 2022 Read Opinion Uncertainty
New patented medicines regulations reflect the general evidence deficiency in Canadian pharmaceutical policy
Brett Skinner | Financial Post, Hill Times | 6 JUL 2022 Read Opinion New drug
National drug plan process doesn’t add up
Nigel Rawson | Hamilton Spectator | 17 FEB 2022
Severely reducing drug prices by federal regulation will harm not help patients
Nigel Rawson, John Adams and Beth Vanstone | National Newswatch | 5 FEB 2022